Prescient Therapeutics (ASX: PTX) has been invited to present clinical data at the prestigious American Society of Hematology (ASH) Annual Meeting in December.

The data relates to the abstract for results of the Phase 1b study in T Cell Lymphomas (TCLs), and comes off the back of exciting results that may propel PTX towards a pivotal Phase 2 trial for efficacy.

In its 65th year, the ASH Annual Meeting will take place on 9-12 December 2023 in San Diego, California. It is the largest and most comprehensive haematology conference in the world, where international pharmaceutical and biotech companies; physicians and researchers gather to discuss the latest advancements and innovations in haematological diseases. Last year, over 25,000 attendees participated in the ASH Annual Meeting. 

Managing Director and CEO of Prescient, Steven Yatomi-Clarke, said having the abstract presented is a “huge honour” that is “a validation of the quality and relevance of the clinical data we are generating in T cell lymphomas, which is an area of unmet clinical need.”

Mr Yatomi-Clarke noted having the Phase 1b abstract accepted by ASH is a “testament to the hard work by the Prescient team and our clinical collaborators.”

“Prescient looks forward to presenting this data at ASH and will release this data to the market concurrently.”

An area of unmet need

TCL is an area of unmet need, with poor patient outcomes.  Existing therapies are typically characterised by a high occurrence of serious toxicities, low response rates (less than 30%) and a short duration of responses (3-4 months) . The median progression free survival rate for r/r PTCL patients with current therapies is just 3-4 months.  

Therapies that are able to improve these outcomes would be welcome by patients and clinicians alike.

Stay up to date with Prescient Therapeutics news and announcements, and receive invites to upcoming events by registering your details here.

Reach Corporate provides Corporate Advisory Services, including managing investor communications on behalf of Prescient Therapeutics Limited and may receive fees for its services.

Past performance is not a reliable indicator of future performance.